|
|
|
| home > white papers > 7 Common Myths about QP Training Debunked: A Guide for Senior Managers - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
7 Common Myths about QP Training Debunked: A Guide for Senior Managers
|
|
The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations
The Janssen Pharmaceutical Companies of Johnson & Johnson today
announced results from the Phase 1 CHRYSALIS study evaluating
amivantamab (JNJ-6372) in the treatment of patients with advanced
non-small cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and
MET-targeted bispecific antibody, which targets activating and
resistance EGFR mutations, and MET pathway activation.
More info >> |
|
 |
White Papers |
 |
|
Pharmaceutical Companies: Outsourcing Combination Product Manufacturing
Phillips-Medisize
Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >> |
|
 |
Industry Events |
 |
Evolution Summit
20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL
The 22nd Evolution Summit is the premium forum bringing leading drug
development executives and solution providers together. As an
invitation-only event, taking place behind closed doors, the Summit
offers an intimate environment for a focused discussion of key new
drivers shaping drug development.
More info >> |
|
|
|
